The UK Life Sciences Industrial Strategy should be required reading for every healthcare leader in the UK. It makes clear that the NHS must be an active participant with industry in delivering the shared objective of outstanding patient outcomes.
The ABPI has produced this sourcebook to support pharmaceutical companies in working successfully and collaboratively with patients and patient organizations.
Pharmaceutical companies are doing everything in their power to avoid disruption to the supply of medicines in all Brexit scenarios. This includes increasing stocks of medicine in the UK, changing supply routes, transferring medicine licenses and duplicating testing in the EU.
The UK has robust measures in place to ensure that medicines and vaccines are both clinically and cost effective before they can be used in the NHS.
Millions of people wouldn't be here today if it wasn't for life-changing science. And many more wouldn't be living the lives they do.
15 August 2019
The Department of Health and Social Care is leading a procurement exercise for an express freight service as part of the government’s plans to support continuity of supply when the UK leaves the EU on 31 October.
09 August 2019
The Prime Minister has announced proposals to shake up immigration rules to help attract scientists to the UK.
01 August 2019
The Treasury has announced an extra £2.1 billion to fund preparations for 'no deal', including £434 million towards ensuring continuity of supply of medicines.
24 July 2019
The ABPI welcomed Boris Johnson's appointment as Prime Minister.
19 August 2019
The Prime Minister has demanded urgent action to tackle declining vaccination rates for MMR. This is the right approach, says Dr Sheuli Porkess of the ABPI.
20 June 2019
Jamie Harvey from AstraZeneca is one of around 40,000 people employed in medicines manufacturing in the UK. He gives his perspective on what it’s like to be an apprentice in the sector.